$AXON

Williams Jeri sold $194K of AXON

Williams Jeri sold 406 shares of AXON ENTERPRISE, INC. (AXON) at $477.43 ($0.19M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Jeri
Published Jun 2, 2026, 9:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
medium confidence
Mentioned
$AXON
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

The disclosure updates the insider ownership record but does not introduce new company fundamentals; 10b5-1 pre-arrangement generally dampens interpretive value.

02

Market read

Primarily a transparency datapoint for insider activity; likely low incremental trading impact absent other catalysts.

03

What to watch

The filing doesn’t state motivation or whether other insiders are selling/buying concurrently; without context on total insider activity, signal is weak.

Relevance 6/10Novelty 6/10Timing: Filed after-hours (SEC Form 4 posted 2026-06-02; sale dated 2026-06-01)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Axon Enterprise, Inc.

Company-level read

Ticker impact

$AXONNeutralMedium confidence
Context

Axon director Jeri Williams sold 406 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via SEC Form 4.

Expected impact

Likely limited near-term price impact; any reaction should be small and quickly mean-reverting unless accompanied by other news.

Evidence & confidence

This is a routine Form 4 datapoint (open-market sale) with explicit 10b5-1 pre-arrangement, and no accompanying operational/financial catalyst is mentioned.

Market effects

Minimal—single insider transaction without additional company or sector catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated or unusually large insider sales can coincide with private information; traders may still monitor for follow-on selling patterns.

Key entities

  • AXON ENTERPRISE, INC.

    Company whose director insider sale was disclosed on SEC Form 4.

  • Williams Jeri

    Director who sold 406 shares on 2026-06-01 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.